Hester Biosciences Ltd's Q4FY25 Quarter Results
- 10 May 2025
Result Summary
- Hester Biosciences Ltd reported a 17.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.3%.
- Its expenses for the quarter were up by 26.2% QoQ and 18.7% YoY.
- The net profit decreased 44.0% QoQ and increased 11.9% YoY.
- The earnings per share (EPS) of Hester Biosciences Ltd stood at 7.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 83.40 | 71.03 | 70.49 | 17.4% | 18.3% |
Total Expenses | 74.01 | 58.64 | 62.35 | 26.2% | 18.7% |
Profit Before Tax | 9.39 | 12.39 | 8.12 | -24.2% | 15.6% |
Tax | 3.47 | 1.96 | 2.71 | 77.0% | 28.0% |
Profit After Tax | 6.39 | 11.41 | 5.71 | -44.0% | 11.9% |
Earnings Per Share | 7.50 | 13.40 | 6.70 | -44.0% | 11.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Hester Biosciences Ltd is a key player in the biotechnology and pharmaceuticals sector, primarily focusing on the production and distribution of vaccines and other related products. The company specializes in animal vaccines, contributing significantly to the veterinary healthcare industry. Hester has a robust presence in the South Asian market, with a growing footprint in other regions. The company has been actively involved in research and development to expand its product line and strengthen its market position. Any recent significant developments about the company are not available based on the provided data.
Revenue
For the fourth quarter of fiscal year 2025, Hester Biosciences Ltd reported a total income of ₹83.40 crores. This represents a quarter-over-quarter (QoQ) increase of 17.4% compared to the third quarter of fiscal year 2025, where the total income was ₹71.03 crores. Furthermore, there was an 18.3% year-over-year (YoY) growth compared to the fourth quarter of fiscal year 2024, when the total income was ₹70.49 crores. These figures indicate a substantial increase in revenue generation over both the previous quarter and the same quarter of the previous year.
Profitability
The company's profitability metrics indicate a mixed performance. Hester Biosciences Ltd recorded a profit before tax of ₹9.39 crores in Q4FY25, which is a decline of 24.2% QoQ from ₹12.39 crores in Q3FY25. However, this represents a YoY increase of 15.6% from ₹8.12 crores in Q4FY24. The tax expenses rose significantly by 77.0% QoQ to ₹3.47 crores in Q4FY25, compared to ₹1.96 crores in Q3FY25, and by 28.0% YoY from ₹2.71 crores in Q4FY24. Consequently, the profit after tax for Q4FY25 stood at ₹6.39 crores, which is a 44.0% decrease QoQ from ₹11.41 crores in Q3FY25, but an 11.9% increase YoY from ₹5.71 crores in Q4FY24. The earnings per share followed a similar trend, with a QoQ decrease of 44.0% and a YoY increase of 11.9%.
Operating Metrics
The financial data from Hester Biosciences Ltd indicates a rise in total expenses, which totaled ₹74.01 crores in Q4FY25. This marks a 26.2% increase QoQ from ₹58.64 crores in Q3FY25 and an 18.7% increase YoY from ₹62.35 crores in Q4FY24. These operating metrics reflect an increase in operational costs, which have outpaced the growth in revenue over the quarter. The rise in expenses could be indicative of increased production costs, investment in research and development, or expansion activities by the company.
